H.C. Wainwright reiterates a Buy rating and $12 price target on shares of Orchestra BioMed (OBIO) after the company announced that the Food and Drug Administration grated Breakthrough Device designation for atrioventricular interval modulation therapy. The Breakthrough Device designation validates the novelty of the AVIM technology and the unmet medical need, which may involve 7.7M patients in the U.S., the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OBIO:
- Orchestra BioMed announces AVIM therapy-focused satellite symposium at HRS 2025
- Orchestra BioMed receives FDA BDD for AVIM therapy
- Orchestra BioMed’s Strategic Advances in Medical Innovations
- Orchestra BioMed price target lowered to $12 from $14 at H.C. Wainwright
- OBIO Upcoming Earnings Report: What to Expect?